



(51) International Patent Classification:
C07K 16/18 (2006.01) *C07K 16/40* (2006.01)
C07K 16/36 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/US2017/025784

(22) International Filing Date:
3 April 2017 (03.04.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/317,897 4 April 2016 (04.04.2016) US

(71) Applicant: TRUE NORTH THERAPEUTICS, INC.
[US/US]; 951 Gateway Boulevard, South San Francisco,
California 94080 (US).

(72) Inventors: PANICKER, Sandip; 951 Gateway Boulevard,
South San Francisco, California 94080 (US). PARRY,
Graham; 951 Gateway Boulevard, South San Francisco,
California 94080 (US). CHRISTOPHERSON, Karen
Sue; 906 E. 3rd Avenue, San Mateo, California 94401

(US). BYUN, Tony SangYoung; 234 Crescent Court,
Brisbane, California 94005 (US).

(74) Agent: JI-EUN, Kim; Sterne, Kessler, Goldstein & Fox
P.L.L.C., 1100 New York Avenue, N.W., Washington, DC
20005-3934 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF

(57) Abstract: The present disclosure provides anti-complement factor Bb antibodies, and compositions comprising the antibodies. The anti-Bb antibodies are useful for treating complement-mediated disorders. The present disclosure provides methods of treating complement-mediated disorders.




FIG. 1



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

Published:

— *with international search report (Art. 21(3))*